7/28/2019 COMMEDfinalMED38.docx

1/9

final QM4-14

QM 4

QM []

QM8

]

QM5 - 10

QM6 - 15

QM7+8 - 10

QM9+10+11 - 40 ]

QM12 - 15

QM13 - 5

QM14 - 5

QM10

=0=

QM 5 -

-

]

-

7/28/2019 COMMEDfinalMED38.docx

2/9

-

-

-

-

-

-

-

]

QM 6 -

- incident rate ratio

person time at risk

- incident rate [ odd ratio , risk ratio , hazard ratio ]

- case control cohortstudy

case control

cohort study

- cross section descriptive study analytical cross sectional study

-

-

7/28/2019 COMMEDfinalMED38.docx

3/9

-

factor

- case controlstudy

recall bias-

crossectional study

- matching

information bias , selection bias , confounding bias

-

selection bias

QM7+8

-

( 5 year survival rate)

type II error-

Inclusion & exclusion criteria-

-

Diclofenac

relative risk [RR]

diclofenac

2

7/28/2019 COMMEDfinalMED38.docx

4/9

-

-

]

-

cohort study- subject

compliance-

perprotocal analysis [

]

-

single blinded-

2

]-

recall bias

7/28/2019 COMMEDfinalMED38.docx

5/9

QM 9 + 10 + 11

-

-

test

-

outcome

-

-

meta analysis-

heterogenicity test-

oxidant

1 anti oxidant placebo

-

forest plot

- funnel plot- ]

funnel plot-

general search engine-

text book [ ]

- foreground Q

- background Q

- ]

control

7/28/2019 COMMEDfinalMED38.docx

6/9

- ] intervention

simvastatin

-

case control [ N of 1 , RCT , systematic review , cohort]-

arrhythmai

strength-

reversibility-

Positive predictive value-

prevalence-

-sensitivity

-specificity-positive predictive value [

]

-negative predictive value [ positive]

-positive likelihood ratio [

]

-negative likelihood ratio

-

positive likelihood

, spec

ratio -

% 100

pretest odd x likelihood = post test odd

post test odd

prevalence = odd / 1+odd

7/28/2019 COMMEDfinalMED38.docx

7/9

]

-accuracy = TP+TN/ = [sen x prevalence] + [ spec x (1-prevalence)]

med37

QM10

56. simvastatin

A. General search engine*****( ^^)

B. Research journal database

C. Systematic review

D. UpToDate

E. Textbook

QM 12

QM

-

HIV

-

- inform consent -

- ]

-

= =

-

-

-

7/28/2019 COMMEDfinalMED38.docx

8/9

-

well known investigator-

77. )

- HIV

87.

- -()

-*****

-

-

82.

A.

B.

C.

TT

D.

E.

90.

a.reserch value & validity

b.appropiate inclusion & exclusion criteria

c.aceptable benefit risk ratio

d.well-known investigator

7/28/2019 COMMEDfinalMED38.docx

9/9

[]

-

-

QM 14

-

outcome-

[

= =]

-

80

]

16-Economic evaluation

-

-

cost effectiveness analysis